Paolo Puccetti

List of Publications by Year in Descending Order

261 papers	20,491 citations	72 h-index	139 g-index
272 ext. papers	22,448 ext. citations	8.8 avg, IF	6.17 L-index

#	Paper	IF	Citations
261	T cell fat catabolism: A novel target for kynurenine?. *EBioMedicine*, **2021**, 75, 103779	8.8	0
260	Tryptophan Metabolites at the Crossroad of Immune-Cell Interaction via the Aryl Hydrocarbon Receptor: Implications for Tumor Immunotherapy. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	7
259	Novel mutations in the WFS1 gene are associated with Wolfram syndrome and systemic inflammation. *Human Molecular Genetics*, **2021**, 30, 265-276	5.6	6
258	Aspergillus fumigatus tryptophan metabolic route differently affects host immunity. *Cell Reports*, **2021**, 34, 108673	10.6	4
257	Off-label therapy targeting pathogenic inflammation in COVID-19. *Cell Death Discovery*, **2020**, 6, 49	6.9	13
256	Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 3848-3857	11.5	34
255	HOPS/TMUB1 retains p53 in the cytoplasm and sustains p53-dependent mitochondrial apoptosis. *EMBO Reports*, **2020**, 21, e48073	6.5	10
254	Pharmacologic Induction of Endotoxin Tolerance in Dendritic Cells by L-Kynurenine. *Frontiers in Immunology*, **2020**, 11, 292	8.4	12
253	Class IA PI3Ks regulate subcellular and functional dynamics of IDO1. *EMBO Reports*, **2020**, 21, e49756	6.5	12
252	Reply to Han et al.: On track for an IDO1-based personalized therapy in autoimmunity. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 24037-24038	11.5	1
251	Engagement of Nuclear Coactivator 7 by 3-Hydroxyanthranilic Acid Enhances Activation of Aryl Hydrocarbon Receptor in Immunoregulatory Dendritic Cells. *Frontiers in Immunology*, **2019**, 10, 1973	8.4	27
250	IL-35Ig-expressing dendritic cells induce tolerance via Arginase 1. *Journal of Cellular and Molecular Medicine*, **2019**, 23, 3757-3761	5.6	4
249	Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis. *Expert Opinion on Drug Discovery*, **2019**, 14, 1199-1212	6.2	16
248	Immunoregulatory Interplay Between Arginine and Tryptophan Metabolism in Health and Disease. *Frontiers in Immunology*, **2019**, 10, 1565	8.4	29
247	Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. *Pharmacology & Therapeutics*, **2019**, 196, 105-116	13.9	56
246	Binding Mode and Structure-Activity Relationships of ITE as an Aryl Hydrocarbon Receptor (AhR) Agonist. *ChemMedChem*, **2018**, 13, 270-279	3.7	11
245	S1P promotes migration, differentiation and immune regulatory activity in amniotic-fluid-derived stem cells. *European Journal of Pharmacology*, **2018**, 833, 173-182	5.3	4

244	Deficiency of immunoregulatory indoleamine 2,3-dioxygenase 1in juvenile diabetes. *JCI Insight*, **2018**, 3,	9.9	36
243	Prospective Study of the Immunological Mechanisms of Immune Tolerance Induction in Severe Haemophilia a Patients with Inhibitors: Preliminary Analysis of a Multi-Center Longitudinal Study. *Blood*, **2018**, 132, 3781-3781	2.2	
242	Immune Checkpoint Molecules, Personalized Immunotherapy, and Autoimmune Diabetes. *Trends in Molecular Medicine*, **2018**, 24, 931-941	11.5	17
241	Reply to ΔF508del-CFTR is not corrected by thymosin β4 *Nature Medicine*, **2018**, 24, 891-893	50.5	2
240	A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells. *Immunity*, **2017**, 46, 233-244	32.3	154
239	Thymosin β4 represents a potential potent single-molecule-based therapy for cystic fibrosis. *Nature Medicine*, **2017**, 23, 590-600	50.5	75
238	Interaction of 7-Alkoxycoumarins with the Aryl Hydrocarbon Receptor. *Journal of Natural Products*, **2017**, 80, 1939-1943	4.9	10
237	Amino-acid sensing and degrading pathways in immune regulation. *Cytokine and Growth Factor Reviews*, **2017**, 35, 37-45	17.9	44
236	Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1. *Journal of Cellular and Molecular Medicine*, **2017**, 21, 165-176	5.6	39
235	The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes. *Frontiers in Immunology*, **2017**, 8, 428	8.4	20
234	Disease Tolerance Mediated by Phosphorylated Indoleamine-2,3 Dioxygenase Confers Resistance to a Primary Fungal Pathogen. *Frontiers in Immunology*, **2017**, 8, 1522	8.4	5
233	CpG Type A Induction of an Early Protective Environment in Experimental Multiple Sclerosis. *Mediators of Inflammation*, **2017**, 2017, 1380615	4.3	3
232	Allosteric modulation of metabotropic glutamate receptor 4 activates IDO1-dependent, immunoregulatory signaling in dendritic cells. *Neuropharmacology*, **2016**, 102, 59-71	5.5	22
231	Azithromycin protects mice against ischemic stroke injury by promoting macrophage transition towards M2 phenotype. *Experimental Neurology*, **2016**, 275 Pt 1, 116-25	5.7	61
230	Installing FVIII-Specific Tolerance in Hemophilia Via Engagement of the Aryl Hydrocarbon Receptor By Tryptophan Derivatives. *Blood*, **2016**, 128, 2563-2563	2.2	
229	The Coevolution of IDO1 and AhR in the Emergence of Regulatory T-Cells in Mammals. *Frontiers in Immunology*, **2015**, 6, 58	8.4	34
228	Comparative proteomic analysis of two distinct stem-cell populations from human amniotic fluid. *Molecular BioSystems*, **2015**, 11, 1622-32		6
227	CD103(+) Dendritic Cells Control Th17 Cell Function in the Lung. *Cell Reports*, **2015**, 12, 1789-801	10.6	65

226	LPS-conditioned dendritic cells confer endotoxin tolerance contingent on tryptophan catabolism. *Immunobiology*, **2015**, 220, 315-21	3.4	23
225	The cross-talk between opportunistic fungi and the mammalian host via microbiotaS metabolism. *Seminars in Immunopathology*, **2015**, 37, 163-71	12	38
224	Stem cells from human amniotic fluid exert immunoregulatory function via secreted indoleamine 2,3-dioxygenase1. *Journal of Cellular and Molecular Medicine*, **2015**, 19, 1593-605	5.6	34
223	Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers. *PLoS ONE*, **2015**, 10, e0122046	3.7	45
222	IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. *Journal of Clinical Investigation*, **2015**, 125, 3766-81	15.9	34
221	Romani & Puccetti reply. *Nature*, **2014**, 514, E18	50.4	1
220	Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E832-40	5.6	63
219	Microbiota control of a tryptophan-AhR pathway in disease tolerance to fungi. *European Journal of Immunology*, **2014**, 44, 3192-200	6.1	58
218	Aryl hydrocarbon receptor control of a disease tolerance defence pathway. *Nature*, **2014**, 511, 184-90	50.4	436
217	NEDD4 controls the expression of GUCD1, a protein upregulated in proliferating liver cells. *Cell Cycle*, **2014**, 13, 1902-11	4.7	20
216	On the Non-Redundant Roles of TDO2 and IDO1. *Frontiers in Immunology*, **2014**, 5, 522	8.4	1
215	Forced IDO1 expression in dendritic cells restores immunoregulatory signalling in autoimmune diabetes. *Journal of Cellular and Molecular Medicine*, **2014**, 18, 2082-91	5.6	41
214	Ligand binding and functional selectivity of L-tryptophan metabolites at the mouse aryl hydrocarbon receptor (mAhR). *Journal of Chemical Information and Modeling*, **2014**, 54, 3373-83	6.1	34
213	TLRs and tryptophan metabolism at the crossroad of immunoregulatory pathways **2014**, 1,		3
212	High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway. *Nature Communications*, **2013**, 4, 1852	17.4	68
211	Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. *Immunity*, **2013**, 39, 372-85	32.3	1141
210	Th17/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxygenase deficiency but corrected by kynurenines. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 609-20	10.2	67
209	IL-22 and IDO1 affect immunity and tolerance to murine and human vaginal candidiasis. *PLoS Pathogens*, **2013**, 9, e1003486	7.6	85

208	Clotting factor concentrate switching and inhibitor development in hemophilia A. *Blood*, **2012**, 120, 720-7	2.2	37
207	Sensing of mammalian IL-17A regulates fungal adaptation and virulence. *Nature Communications*, **2012**, 3, 683	17.4	71
206	Indoleamine 2,3-dioxygenase: from catalyst to signaling function. *European Journal of Immunology*, **2012**, 42, 1932-7	6.1	136
205	A GpC-rich oligonucleotide acts on plasmacytoid dendritic cells to promote immune suppression. *Journal of Immunology*, **2012**, 189, 2283-9	5.3	19
204	Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. *Nature Immunology*, **2011**, 12, 870-8	19.1	483
203	Indoleamine 2,3-Dioxygenase and Peripheral Tolerance to Exogenous Factor VIII: A Multi-Centre Pilot Study. *Blood*, **2011**, 118, 26-26	2.2	
202	Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. *Nature Medicine*, **2010**, 16, 897-902	50.5	117
201	XENOGRAFT OF MICROENCAPSULATED SERTOLI CELLS ALONE CURES NOD MICE WITH SPONTANEOUS AUTOIMMUNE DIABETES. *Transplantation*, **2010**, 90, 329	1.8	
200	IL-22 defines a novel immune pathway of antifungal resistance. *Mucosal Immunology*, **2010**, 3, 361-73	9.2	208
199	Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. *Gut*, **2010**, 59, 595-604	19.2	264
198	Xenograft of microencapsulated sertoli cells reverses T1DM in NOD mice by inducing neogenesis of beta-cells. *Transplantation*, **2010**, 90, 1352-7	1.8	14
197	Proteasomal Degradation of Indoleamine 2,3-Dioxygenase in CD8 Dendritic Cells is Mediated by Suppressor of Cytokine Signaling 3 (SOCS3). *International Journal of Tryptophan Research*, **2010**, 3, 91-7	5.6	21
196	Indoleamine 2,3-dioxygenase (IDO) in inflammation and allergy to Aspergillus. *Medical Mycology*, **2009**, 47 Suppl 1, S154-61	3.9	15
195	IDO mediates TLR9-driven protection from experimental autoimmune diabetes. *Journal of Immunology*, **2009**, 183, 6303-12	5.3	96
194	Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans. *Mucosal Immunology*, **2009**, 2, 362-74	9.2	110
193	Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone. *Journal of Experimental Medicine*, **2009**, 206, 2511-26	16.6	75
192	Indoleamine 2,3-Dioxygenase: Transcriptional Regulation and Autoimmunity **2009**, 95-116		
191	Chronic granulomatous disease. *Cellular and Molecular Life Sciences*, **2009**, 66, 553-8	10.3	19

190	Indoleamine 2,3-dioxygenase in infection: the paradox of an evasive strategy that benefits the host. *Microbes and Infection*, **2009**, 11, 133-41	9.3	99
189	TGF-beta and kynurenines as the key to infectious tolerance. *Trends in Molecular Medicine*, **2009**, 15, 41-9	11.5	107
188	Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. *Nature*, **2008**, 451, 211-5	50.4	449
187	Generation of T cell regulatory activity by plasmacytoid dendritic cells and tryptophan catabolism. *Blood Cells, Molecules, and Diseases*, **2008**, 40, 101-5	2.1	49
186	Immune regulation and tolerance to fungi in the lungs and skin. *Chemical Immunology and Allergy*, **2008**, 94, 124-137		17
185	Cutting edge: Autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. *Journal of Immunology*, **2008**, 181, 5194-8	5.3	137
184	IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 178, 1023-32	10.2	332
183	IL-17 and therapeutic kynurenines in pathogenic inflammation to fungi. *Journal of Immunology*, **2008**, 180, 5157-62	5.3	101
182	Lack of Toll IL-1R8 exacerbates Th17 cell responses in fungal infection. *Journal of Immunology*, **2008** , 180, 4022-31	5.3	91
181	SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 20828-33	11.5	155
180	Innovative extraction procedure for obtaining high pure lycopene from tomato. *European Food Research and Technology*, **2008**, 226, 327-335	3.4	27
179	CTLA-4-immunoglobulin and indoleamine 2,3-dioxygenase in dominant tolerance **2008**, 87-106		
178	Controlling pathogenic inflammation to fungi. *Expert Review of Anti-Infective Therapy*, **2007**, 5, 1007-17	5.5	44
177	On watching the watchers: IDO and type I/II IFN. *European Journal of Immunology*, **2007**, 37, 876-9	6.1	62
176	IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. *European Journal of Immunology*, **2007**, 37, 2695-706	6.1	443
175	Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. *Nature Medicine*, **2007**, 13, 579-86	50.5	278
174	IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. *Nature Reviews Immunology*, **2007**, 7, 817-23	36.5	354
173	Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. *Annals of the New York Academy of Sciences*, **2007**, 1112, 326-38	6.5	72

172	Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and IDO-dependent inhibition of Rorc. *Journal of Immunology*, **2007**, 179, 5999-6008	5.3	140
171	Tryptophan catabolism in IDO+ plasmacytoid dendritic cells. *Current Drug Metabolism*, **2007**, 8, 209-16	3.5	53
170	Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes. *Transplantation*, **2007**, 84, S17-20	1.8	70
169	Receptors and pathways in innate antifungal immunity: the implication for tolerance and immunity to fungi. *Advances in Experimental Medicine and Biology*, **2007**, 590, 209-21	3.6	16
168	Toll-like receptor 9-mediated induction of the immunosuppressive pathway of tryptophan catabolism. *European Journal of Immunology*, **2006**, 36, 8-11	6.1	50
167	The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. *Journal of Immunology*, **2006** , 176, 6752-61	5.3	789
166	Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. *Journal of Immunology*, **2006**, 177, 130-7	5.3	150
165	Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. *Journal of Immunology*, **2006**, 176, 1712-23	5.3	170
164	IL-23 neutralization protects mice from Gram-negative endotoxic shock. *Cytokine*, **2006**, 34, 161-9	4	20
163	Protective tolerance to fungi: the role of IL-10 and tryptophan catabolism. *Trends in Microbiology*, **2006**, 14, 183-9	12.4	116
162	Tryptophan catabolism generates autoimmune-preventive regulatory T cells. *Transplant Immunology*, **2006**, 17, 58-60	1.7	85
161	Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. *Blood*, **2006**, 108, 2265-74	2.2	148
160	Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. *Blood*, **2006**, 107, 2846-54	2.2	166
159	Enhanced tryptophan catabolism in the absence of the molecular adapter DAP12. *European Journal of Immunology*, **2005**, 35, 3111-8	6.1	38
158	CD40 ligation prevents onset of tolerogenic properties in human dendritic cells treated with CTLA-4-Ig. *Microbes and Infection*, **2005**, 7, 1040-8	9.3	21
157	Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells. *International Immunology*, **2005**, 17, 1429-38	4.9	67
156	A crucial role for tryptophan catabolism at the host/Candida albicans interface. *Journal of Immunology*, **2005**, 174, 2910-8	5.3	119
155	Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. *Journal of Immunology*, **2005**, 174, 6582-6	5.3	88

154	CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. *Journal of Experimental Medicine*, **2004**, 200, 1051-62	16.6	111
153	The exploitation of distinct recognition receptors in dendritic cells determines the full range of host immune relationships with Candida albicans. *International Immunology*, **2004**, 16, 149-61	4.9	76
152	Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. *Journal of Immunology*, **2004**, 173, 3748-54	5.3	183
151	CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. *Nature Immunology*, **2004**, 5, 1134-42	19.1	226
150	A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. *Journal of Experimental Medicine*, **2003**, 198, 153-60	16.6	181
149	Modulation of tryptophan catabolism by regulatory T cells. *Nature Immunology*, **2003**, 4, 1206-12	19.1	1026
148	Adaptation of Candida albicans to the host environment: the role of morphogenesis in virulence and survival in mammalian hosts. *Current Opinion in Microbiology*, **2003**, 6, 338-43	7.9	94
147	Tolerance, DCs and tryptophan: much ado about IDO. *Trends in Immunology*, **2003**, 24, 242-8	14.4	626
146	Response to von Bubnoff et al.: Still new perspectives on IDO function?. *Trends in Immunology*, **2003**, 24, 297	14.4	
145	CTLA-4, T helper lymphocytes and dendritic cells: an internal perspective of T-cell homeostasis. *Trends in Molecular Medicine*, **2003**, 9, 133-5	11.5	15
144	Response from Romani et al.: Microbial virulence results from the interaction between host and microorganism. *Trends in Microbiology*, **2003**, 11, 158-159	12.4	6
143	Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. *Journal of Immunology*, **2003**, 171, 2581-7	5.3	98
142	Tryptophan catabolism in nonobese diabetic mice. *Advances in Experimental Medicine and Biology*, **2003**, 527, 47-54	3.6	19
141	T cell apoptosis by tryptophan catabolism. *Cell Death and Differentiation*, **2002**, 9, 1069-77	12.7	722
140	CTLA-4-Ig regulates tryptophan catabolism in vivo. *Nature Immunology*, **2002**, 3, 1097-101	19.1	970
139	CD40 ligand and CTLA-4 are reciprocally regulated in the Th1 cell proliferative response sustained by CD8(+) dendritic cells. *Journal of Immunology*, **2002**, 169, 1182-8	5.3	19
138	The immunosuppressive activity of proinflammatory cytokines in experimental models: potential for therapeutic intervention in autoimmunity. *Inflammation and Allergy: Drug Targets*, **2002**, 1, 77-87		15
137	Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. *International Immunology*, **2002**, 14, 65-8	4.9	218

136	IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. *Journal of Immunology*, **2002**, 168, 5448-54	5.3	196
135	Fungi, dendritic cells and receptors: a host perspective of fungal virulence. *Trends in Microbiology*, **2002**, 10, 508-14	12.4	112
134	Effects of IL-12 and IL-23 on antigen-presenting cells at the interface between innate and adaptive immunity. *Critical Reviews in Immunology*, **2002**, 22, 373-90	1.8	19
133	IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic cells expressing indoleamine 2,3-dioxygenase. *Journal of Immunology*, **2001**, 167, 708-14	5.3	156
132	CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. *Journal of Immunology*, **2001**, 166, 277-83	5.3	122
131	Positive regulatory role of IL-12 in macrophages and modulation by IFN-gamma. *Journal of Immunology*, **2001**, 167, 221-7	5.3	82
130	IFN-gamma inhibits presentation of a tumor/self peptide by CD8 alpha- dendritic cells via potentiation of the CD8 alpha+ subset. *Journal of Immunology*, **2000**, 165, 1357-63	5.3	90
129	IL-9 protects mice from Gram-negative bacterial shock: suppression of TNF-alpha, IL-12, and IFN-gamma, and induction of IL-10. *Journal of Immunology*, **2000**, 164, 4197-203	5.3	59
128	Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo. *Journal of Immunology*, **2000**, 165, 5495-501	5.3	74
127	IL-12 induces SDS-stable class II alphabeta dimers in murine dendritic cells. *Cytokine*, **2000**, 12, 401-4	4	7
126	Dual effect of IL-4 on resistance to systemic gram-negative infection and production of TNF-alpha. *Cytokine*, **2000**, 12, 417-21	4	18
125	Immunogenicity of tumor peptides: importance of peptide length and stability of peptide/MHC class II complex. *Cancer Immunology, Immunotherapy*, **1999**, 48, 195-203	7.4	14
124	IL-12 acts selectively on CD8 alpha- dendritic cells to enhance presentation of a tumor peptide in vivo. *Journal of Immunology*, **1999**, 163, 3100-5	5.3	48
123	IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. *Immunity*, **1998**, 9, 315-23	32.3	244
122	Dendritic cells, interleukin 12, and CD4+ lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide. *Critical Reviews in Immunology*, **1998**, 18, 87-98	1.8	34
121	Initiation of T-helper cell immunity to Candida albicans by IL-12: the role of neutrophils. *Chemical Immunology and Allergy*, **1997**, 68, 110-35		59
120	Interleukin-12 in infectious diseases. *Clinical Microbiology Reviews*, **1997**, 10, 611-36	34	176
119	Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells. *Cellular Immunology*, **1997**, 181, 109-19	4.4	4

118	Dendritic cells and interleukin 12 as adjuvants for tumor-specific vaccines. *Advances in Experimental Medicine and Biology*, **1997**, 417, 579-82	3.6	4
117	A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. *Journal of Immunology*, **1997**, 158, 3593-602	5.3	88
116	Evidence for tumor necrosis factor alpha as a mediator of the toxicity of a cyclooxygenase inhibitor in Gram-negative sepsis. *European Journal of Pharmacology*, **1996**, 307, 191-9	5.3	13
115	Neutrophils and the adaptive immune response to Candida albicans. *Research in Immunology*, **1996**, 147, 512-8		20
114	Biological Role of Th Cell Subsets in Candidiasis. *Chemical Immunology and Allergy*, **1996**, 63, 115-137		33
113	A retroviral peptide encoded by mutated env p15E gene is recognized by specific CD8+ T lymphocytes on drug-treated murine mastocytoma P815. *International Journal of Immunopharmacology*, **1996**, 18, 563-76		6
112	Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. *Journal of Experimental Medicine*, **1996**, 183, 1345-55	16.6	259
111	IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. *Journal of Immunology*, **1996**, 157, 1589-97	5.3	38
110	Biological role of Th cell subsets in candidiasis. *Chemical Immunology and Allergy*, **1996**, 63, 115-37		18
109	T helper cell dichotomy to Candida albicans: implications for pathology, therapy, and vaccine design. *Immunologic Research*, **1995**, 14, 148-62	4.3	24
108	T helper cell type 1 (Th1)- and Th2-like responses are present in mice with gastric candidiasis but protective immunity is associated with Th1 development. *Journal of Infectious Diseases*, **1995**, 171, 1279-88	7	113
107	IL12 in Candida albicans infections. *Research in Immunology*, **1995**, 146, 532-8		33
106	Anticancer drug toxicity via cytokine production: the hydroxyurea paradigm. *Toxicology Letters*, **1995**, 82-83, 167-71	4.4	2
105	A TH1-TH2-like switch in candidiasis: new perspectives for therapy. *Trends in Microbiology*, **1995**, 3, 237-40	12.4	106
104	Interleukin-4 and -10 exacerbate candidiasis in mice. *European Journal of Immunology*, **1995**, 25, 1559-65	6.1	109
103	CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide. *European Journal of Immunology*, **1995**, 25, 2797-802	6.1	25
102	TGF-beta is important in determining the in vivo patterns of susceptibility or resistance in mice infected with Candida albicans. *Journal of Immunology*, **1995**, 155, 1349-60	5.3	52
101	Multiple point mutations in an endogenous retroviral gene confer high immunogenicity on a drug-treated murine tumor. *Journal of Immunology*, **1995**, 154, 4630-41	5.3	11

100	Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. *Journal of Infectious Diseases*, **1994**, 169, 1325-31	7	86
99	Endogenous retroviral gp70 genes of the murine lymphoma L5178Y: analysis of restriction fragment polymorphism upon induction of drug-mediated immunogenicity. *Viral Immunology*, **1994**, 7, 155-67	1.7	3
98	Interleukin-12 but not interferon-gamma production correlates with induction of T helper type-1 phenotype in murine candidiasis. *European Journal of Immunology*, **1994**, 24, 909-15	6.1	75
97	Use of a skin test assay to determine tumor-specific CD8+ T cell reactivity. *European Journal of Immunology*, **1994**, 24, 1446-52	6.1	30
96	Cytokines and tumours: problems and perspectives. *Pharmacological Research*, **1994**, 29, 111-9	10.2	1
95	Mechanisms of cell-mediated immunity in fungal infection. *Medical Mycology*, **1994**, 32 Suppl 1, 123-31	3.9	8
94	Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans. *Journal of Immunology*, **1994**, 152, 3514-21	5.3	120
93	IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. *Journal of Immunology*, **1994**, 153, 5167-75	5.3	73
92	Tolerance to staphylococcal enterotoxin B initiated Th1 cell differentiation in mice infected with Candida albicans. *Infection and Immunity*, **1994**, 62, 4047-53	3.7	13
91	Mucosal and systemic T helper cell function after intragastric colonization of adult mice with Candida albicans. *Journal of Infectious Diseases*, **1993**, 168, 1449-57	7	59
90	Immunogenic properties of retroviral protein P15E from drug-treated murine mastocytoma P815. *International Journal of Cancer*, **1993**, 55, 344-50	7.5	6
89	Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans. *European Journal of Immunology*, **1993**, 23, 1034-8	6.1	227
88	Cell-mediated immunity to chemically xenogenized tumors--VI. The effect of cell treatment with retroviral env antisense oligonucleotides. *International Journal of Immunopharmacology*, **1993**, 15, 567-72		
87	Accelerated hematopoietic recovery and protective effect of the cyclooxygenase inhibitor indomethacin in bacterial infection of neutropenic mice. *Cellular Immunology*, **1993**, 147, 341-52	4.4	12
86	CD4+ subset expression in murine candidiasis. Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance. *Journal of Immunology*, **1993**, 150, 925-31	5.3	114
85	Natural killer cells do not play a dominant role in CD4+ subset differentiation in Candida albicans-infected mice. *Infection and Immunity*, **1993**, 61, 3769-74	3.7	29
84	Anti-Cytokine Therapy of Murine Candidiasis **1993**, 195-200		
83	Chemical Xenogenization of Experimental Tumors by Antineoplastic Drugs **1993**, 147-161		

82	Course of primary candidiasis in T cell-depleted mice infected with attenuated variant cells. *Journal of Infectious Diseases*, **1992**, 166, 1384-92	7	42
81	Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis. *Journal of Experimental Medicine*, **1992**, 176, 19-25	16.6	187
80	Experimental studies of immunotoxicity of a photosensitizing agent (Photofrin II) in mice. *Journal of Chemotherapy*, **1992**, 4, 290-6	2.3	2
79	Molecular and genomic aspects of xenogenizing-alkylating drugs. *Pharmacological Research*, **1992**, 26 Suppl 2, 24-5	10.2	
78	Immune recognition of drug-induced tumor antigens: a study with a nonimmunogenic, revertant clone. *Pharmacological Research*, **1992**, 26 Suppl 2, 186-7	10.2	1
77	Antagonistic effect of IL-2 on DTIC-induced impairment of tumor-specific cell-mediated immunity in vitro. *Pharmacological Research*, **1992**, 26 Suppl 2, 106-7	10.2	1
76	Antigen-specific cytolysis of infected cells in murine candidiasis. *European Journal of Epidemiology*, **1992**, 8, 368-76	12.1	3
75	O6-methylguanine-DNA methyltransferase activity and induction of novel immunogenicity in murine tumor cells treated with methylating agents. *Cancer Chemotherapy and Pharmacology*, **1992** , 29, 277-82	3.5	10
74	Tumor-specific L3T4+ and Lyt-2+ lymphocytes in mice primed to mutagenized cell variants. *International Journal of Immunopharmacology*, **1992**, 14, 915-21		2
73	Modulation of colony-stimulating activity by interleukin 1 in mice: opposing effects of combined treatment with indomethacin or prostaglandin E2. *International Journal of Immunopharmacology*, **1992**, 14, 655-9		3
72	Involvement of the Th1 subset of CD4+ T cells in acquired immunity to mouse infection with Trypanosoma equiperdum. *Cellular Immunology*, **1992**, 143, 261-71	4.4	7
71	Immunogenic tumor variants induced by drug treatment of the L5178Y lymphoma: search for serologically defined antigens at the clonal level. *International Journal of Cancer*, **1992**, 52, 372-7	7.5	8
70	Gamma interferon modifies CD4+ subset expression in murine candidiasis. *Infection and Immunity*, **1992**, 60, 4950-2	3.7	49
69	Combination Therapies with Cytokines and Anti-Cytokines in Murine Opportunistic Infections **1992**, 97-104		
68	Cancer Immunotherapy: Preclinical Studies with Triazene Compounds **1992**, 293-301		
67	Modulation of circulating colony-stimulating activity in mice: combined effects of IL-1 and bacterial or indomethacin treatment. *International Journal of Immunopharmacology*, **1991**, 13, 955-60		2
66	Candida albicans-specific Ly-2+ lymphocytes with cytolytic activity. *European Journal of Immunology* , **1991**, 21, 1567-70	6.1	16
65	Intrasplenic immunization for the induction of humoral and cell-mediated immunity to nitrocellulose-bound antigen. *Journal of Immunological Methods*, **1991**, 137, 9-15	2.5	15

64	Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance. *Infection and Immunity*, **1991**, 59, 4647-54	3.7	145
63	Macrophage colony-stimulating factor in murine candidiasis: serum and tissue levels during infection and protective effect of exogenous administration. *Infection and Immunity*, **1991**, 59, 868-72	3.7	67
62	Antibacterial resistance induced by recombinant interleukin 1 in myelosuppressed mice: effect of treatment schedule and correlation with colony-stimulating activity in the bloodstream. *Cellular Immunology*, **1990**, 128, 250-60	4.4	17
61	Identification and immunogenic properties of an 80-kDa surface antigen on a drug-treated tumor variant: relationship to MuLV gp70. *European Journal of Immunology*, **1990**, 20, 629-36	6.1	25
60	T-cell subsets, IFN-gamma production and efferent specificity in anti-parental tumor immunity induced by mouse sensitization with xenogenized variant cells. *International Journal of Cancer*, **1990**, 46, 653-7	7.5	6
59	Cell-mediated immunity to chemically xenogenized tumors. V. Failure of novel antigens to increase the frequency of tumor-specific cytotoxic T cells. *International Journal of Immunopharmacology*, **1990**, 12, 743-9		3
58	T cell subsets and IFN-gamma production in resistance to systemic candidosis in immunized mice. *Journal of Immunology*, **1990**, 144, 4333-9	5.3	59
57	Xenogenization of Experimental Tumors by Triazene Derivatives **1990**, 79-89		2
56	Protective immunity induced by low-virulence Candida albicans: cytokine production in the development of the anti-infectious state. *Cellular Immunology*, **1989**, 124, 334-44	4.4	67
55	Changes in the tumorigenic and metastatic properties of murine melanoma cells treated with a triazene derivative. *Clinical and Experimental Metastasis*, **1989**, 7, 329-41	4.7	7
54	Delayed-type hypersensitivity to tumor antigens co-expressed with immunogenic determinants induced by xenogenization. *International Journal of Cancer*, **1989**, 43, 279-84	7.5	23
53	Cell-mediated immunity to chemically xenogenized tumors--IV. Production of lymphokine activity by, and in response to, highly immunogenic cells. *International Journal of Immunopharmacology*, **1989**, 11, 537-42		7
52	Lack of correlation between DNA-methylating activity and appearance of the immunogenic phenotype in clones of a murine lymphoma treated with mutagens. *Cancer Immunology, Immunotherapy*, **1989**, 29, 139-43	7.4	10
51	Toward characterization of novel drug-induced antigens. *Pharmacological Research*, **1989**, 21, 663-664	10.2	
50	Search for cytogenetic markers in chemically xenogenized murine lymphomas. *Pharmacological Research*, **1989**, 21, 667-668	10.2	
49	Role of L3T4+ lymphocytes in protective immunity to systemic Candida albicans infection in mice. *Infection and Immunity*, **1989**, 57, 3581-7	3.7	65
48	Regulation of tumor antigen expression by drugs acting as mutagens and/or gene activators. *Pharmacological Research Communications*, **1988**, 20, 441-2		
47	Generation of monoclonal antibodies to a chemically xenogenized murine lymphoma. *Pharmacological Research Communications*, **1988**, 20, 443-4		1

46	In vitro evaluation of the immunoactive properties of potentially useful immunopotentiators. *Pharmacological Research Communications*, **1988**, 20, 64		1
45	Pharmacologic manipulation of tumor cell immunogenicity (xenogenization) as a means of inducing their rejection in experimental immunotherapy. *Pharmacological Research Communications*, **1988**, 20, 318		
44	Induction of tumor suppression and delayed-type footpad reaction by transfer of lymphocytes sensitized to a xenogenized tumor variant. *International Journal of Cancer*, **1988**, 42, 71-5	7.5	14
43	Cell-mediated immunity to chemically xenogenized tumors. I. Inhibition by specific antisera and H-2 association of the novel antigens. *Cancer Immunology, Immunotherapy*, **1988**, 26, 48-54	7.4	14
42	Cell-mediated immunity to chemically xenogenized tumors--III. Generation of monoclonal antibodies interfering with reactivity to novel antigens. *International Journal of Immunopharmacology*, **1988**, 10, 803-9		12
41	Cell-mediated immunity to chemically xenogenized tumors. II. Evidence for accessory function and self-antigen presentation by a highly immunogenic tumor variant. *Cellular Immunology*, **1988**, 111, 365-78	4.4	15
40	Immunomodulation by a low-virulence, agerminative variant of Candida albicans. Further evidence for macrophage activation as one of the effector mechanisms of nonspecific anti-infectious protection. *Medical Mycology*, **1988**, 26, 285-99	3.9	71
39	Chemical xenogenization of experimental tumors. *Cancer and Metastasis Reviews*, **1987**, 6, 93-111	9.6	40
38	DNA methylating activity in murine lymphoma cells xenogenized by triazene derivatives. *International Journal of Cancer*, **1987**, 39, 769-73	7.5	13
37	Inhibition of murine lymphoma growth by adoptive transfer of lymphocytes sensitized to a xenogenized tumor variant. *International Journal of Cancer*, **1987**, 40, 7-11	7.5	16
36	DNA methylating activity in murine lymphoma cells treated with xenogenizing chemicals. *Cancer Detection and Prevention Supplement: Official Publication of the International Society for Preventive Oncology, Inc*, **1987**, 1, 311-6		1
35	Amphotericin-B Induced Immunomodulation of Resistance Against CandidaAlbicans Infection **1987**, 91-99		
34	Involvement of host macrophages in the immunoadjuvant activity of amphotericin B in a mouse fungal infection model. *Journal of Antibiotics*, **1986**, 39, 846-55	3.7	15
33	Evidence for macrophage-mediated protection against lethal Candida albicans infection. *Infection and Immunity*, **1986**, 51, 668-74	3.7	197
32	Immunoadjuvant activity of amphotericin B as displayed in mice infected with Candida albicans. *Antimicrobial Agents and Chemotherapy*, **1985**, 27, 625-31	5.9	37
31	Adoptive immunotherapy of intracerebral murine lymphomas: role of different lymphoid populations. *International Journal of Cancer*, **1985**, 35, 659-65	7.5	19
30	Humoral response against murine lymphoma cells xenogenized by drug treatment in vivo. *International Journal of Cancer*, **1985**, 36, 225-31	7.5	24
29	Chemical xenogenization of tumor cells. *Trends in Pharmacological Sciences*, **1985**, 6, 485-487	13.2	14

28	Combined effects of chemotherapy and host antitumor response in a murine histocompatible lymphoma model. *International Journal of Immunopharmacology*, **1984**, 6, 217-22		
27	Chemical xenogenization of murine lymphoma cells with triazene derivatives: immunotoxicological studies. *Cancer Immunology, Immunotherapy*, **1984**, 17, 213-7	7.4	15
26	Enhancement of natural killer cell activity in mice by treatment with a thymic factor. *Cancer Immunology, Immunotherapy*, **1984**, 17, 51-5	7.4	14
25	Modulating Effects of Thymic Factors on Natural Cell-Mediated Reactivities of Natural and Cyclophosphamide-Treated Mice **1984**, 139-144		
24	Systemic adoptive immunotherapy of a highly immunogenic murine lymphoma growing in the brain. *International Journal of Cancer*, **1983**, 31, 477-82	7.5	17
23	Antilymphoma graft responses in the mouse brain: a study of T-dependent functions. *International Journal of Cancer*, **1983**, 31, 769-74	7.5	3
22	Phagocytic killing ofCandida albicansby different murine effector cells. *Medical Mycology*, **1983**, 21, 271-286	3.6	66
21	Correlation between in vivo and in vitro studies of modulation of resistance to experimental Candida albicans infection by cyclophosphamide in mice. *Infection and Immunity*, **1983**, 40, 46-55	3.7	55
20	Natural cell-mediated cytotoxicity against Candida albicans induced by cyclophosphamide: nature of the in vitro cytotoxic effector. *Infection and Immunity*, **1983**, 42, 1-9	3.7	43
19	A radiolabel release microassay for phagocytic killing of Candida albicans. *Journal of Immunological Methods*, **1982**, 52, 369-77	2.5	43
18	Cellular mechanisms underlying the adjuvant activity of Candida albicans in a mouse lymphoma model. *International Journal of Cancer*, **1982**, 29, 483-8	7.5	11
17	Depression of hepatic biotransformations by chemical immunoadjuvants. *Immunopharmacology and Immunotoxicology*, **1981**, 3, 251-64		10
16	Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy. *Cancer Research*, **1981**, 41, 681-7	10.1	26
15	Cytotoxic effector cells with the characteristics of natural killer cells in the lungs of mice. *International Journal of Cancer*, **1980**, 25, 153-8	7.5	57
14	In vivo natural reactivity of mice against tumor cells. *International Journal of Cancer*, **1980**, 25, 475-86	7.5	147
13	Combined effects of antineoplastic agents and anti-lymphoma allograft reactions. *European Journal of Cancer*, **1980**, 16, 23-33		22
12	Adriamycin-induced antitumor response in lethally irradiated mice. *Immunopharmacology*, **1979**, 1, 211-20		18
11	Natural killer cells: characteristics and regulation of activity. *Immunological Reviews*, **1979**, 44, 43-70	11.3	535

10	Cytolytic and cytostatic anti-tumor activities of macrophages from mice injected with murine sarcoma virus. *International Journal of Cancer*, **1979**, 23, 123-32	7.5	49
9	Augmentation of natural killer activity by pyran copolymer in mice. *International Journal of Cancer*, **1979**, 24, 656-61	7.5	26
8	Activation of mouse macrophages by pyran copolymer and role in augmentation of natural killer activity. *International Journal of Cancer*, **1979**, 24, 819-25	7.5	28
7	Rapid in vivo assay of mouse natural killer cell activity. *Journal of the National Cancer Institute*, **1979**, 63, 1041-5	9.7	104
6	Long-term depression of two primary immune responses induced by a single dose of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC). *Experientia*, **1978**, 34, 799-800		16
5	Immunopharmacology of pyran copolymer. *Pharmacological Research Communications*, **1978**, 10, 489-501		6
4	Growth inhibition of normal or drug-treated lymphoma cells in lethally irradiated mice. *Journal of the National Cancer Institute*, **1978**, 60, 1083-90	9.7	12
3	Growth and rejection patterns of murine lymphoma cells antigenically altered following drug treatment in vivo. *Transplantation*, **1978**, 25, 63-8	1.8	19
2	Murine leukemia growth inhibition or enhancement following immunization with tumor cells antigenically altered by drug treatment. *Pharmacological Research Communications*, **1977**, 9, 349-58		3
1	Dendritic Cells in Immunity and Vaccination against Fungi915-934		4